

QUARTERLY REPORTS

Compiled: as at 30 June 2018

For: MARC 13 September 2018

[REDACTED]

[REDACTED]

CONTENTS

Reporting period covered: 2nd Quarter 2018

01 April 2018 to 30 June 2018

Section 1: Overview

[Table 1]	Summary of medicine related reports – reporter type and seriousness	1
[Table 2]	Summary of vaccine related reports – reporter type and seriousness	1

Section 2: Potential Safety Signals

[Table 3]	Safety Signals from Single case reports (No report this quarter)	3
[Table 4]	Safety Signals from Reporting trends (No report this quarter)	3

Section 3: Review of Fatal Cases

[Table 5]	Fatal cases assessed causal	4
-----------	-----------------------------	---

Section 4: Special Populations

[Table 6]	Serious cases associated with medicines in patients under 18 years	6
[Table 7]	Serious cases of serious AEFI terms with vaccines in patients under 18 years	11
[Table 8]	Serious cases of critical terms in patients over 80 years	14
[Table 9]	Causal and Serious cases in patients 18 to 80 years	16

Section 5: Special Reports



Section 1: Overview

Period of Report: 01 April 2018 to 30 June 2018
 Number of Reports received: 1210

Table 1: Summary of medicine related reports [n=655]

Description	Fatal	Other Serious*	Non-serious*	Total
General Practitioners	1	5	82	88
Hospital Doctors		48	71	119
Hospital Pharmacists	2	22	25	49
Community Pharmacists	1	4	70	75
Nurses		10	84	94
Other HC professionals		1	18	19
Pharmaceutical Company	12	33	64	109
Coroner	1			1
ACC	1	1	2	4
Public		13	49	62
Other		5	30	35
Total	18	142*	495*	655

Table 2: Summary of vaccine related reports [n=555]

Description	Fatal	Other Serious*	Non-serious*	Total
General Practitioners	1	1	93	95
Hospital Doctors		5	7	12
Hospital Pharmacists		1		1
Community Pharmacists			7	7
Nurses	1	6	409	416
Other HC professionals				0
Pharmaceutical Company			2	2
Coroner				0
ACC				0
Public		1	15	16
Other		1	5	6
Total	2	15	538	555

* Seriousness is assessed for each report based on the 'result of the adverse reaction(s)'

- Patient Died
- Congenital abnormality
- Patient hospitalisation or prolonged hospitalisation
- Reaction was Life Threatening
- Intervention was required to avoid permanent disability
- Persisting disability

Overview of Reporting




Figure 1: Comparison of Reporters – percentage of reports per Quarter

Section 2: Presentation of Potential Safety Signals

Table 3: Single Case Reports

No reports requiring discussion of regulatory action this quarter

Table 4: Safety Signals from Reporting Trends

No trends requiring discussion of regulatory action this quarter

Section 3: Review of Fatal Cases

Table 5: Fatal Cases assessed causal - April to June 2018

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128852	[REDACTED]	JUN2018	PNEUMONIA SEPSIS	* CLOZAPINE VENLAFAXINE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	88	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
128501	[REDACTED]	MAY2018	SUDDEN DEATH INTENTIONAL OVERDOSE	* CODEINE * OLANZAPINE * ROXITHROMYCIN * NORTRIPTYLINE * DIAZEPAM	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	46	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Fatalities continued.....

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128551	[REDACTED]	MAY2018	GI HAEMORRHAGE MELAENA	* DABIGATRAN	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	77	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
128906	[REDACTED]	JUN2018	GI HAEMORRHAGE CONGESTIVE HEART FAILURE BRADYCARDIA	* DABIGATRAN * DIGOXIN	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	72	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Section 4: Review of Cases in Special Populations (Children and Elderly)

Table 6: Serious cases causally associated with medicines in children under 18 years

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128149	█	APR2018	FOETAL VALPROATE SYNDROME	* VALPROATE SODIUM	█		█	█	2	F	█
█	█	█	█								
█	█	█	█								
128294	█	MAY2018	FOETAL VALPROATE SYNDROME	* VALPROATE SODIUM	█		█	█	birth	F	█
█	█	█	█								
█	█	█	█								
128224	█	APR2018	FIBRILLATION VENTRICULAR CARDIAC ARREST	* DROPERIDOL DEXAMETHASONE AMOXICILLIN/CLAVULANIC ACID	█	█	█	█	17	F	█
█	█	█	█								
█	█	█	█								

Serious Cases in Patients under 18 ...continued

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
129102	█	JUN2018	FEEDING DISORDER NEONATAL SOMNOLENCE NEONATAL RESPIRATORY DISORDER NEONATAL WEIGHT DECREASE NEONATAL	* TRAMADOL	█		█	█	birth	M	█
█	█	█	█	█	█	█	█	█	█	█	█
█	█	█	█	█	█	█	█	█	█	█	█
129098	█	JUN2018	ANAPHYLACTIC REACTION	* IBUPROFEN * AMOXICILLIN	█	█	█	█	2	M	█
█	█	█	█	█	█	█	█	█	█	█	█
128907	█	JUN2018	STEVENS JOHNSON SYNDROME	* AMOXICILLIN	█	█	█	█	4	M	█
█	█	█	█	█	█	█	█	█	█	█	█
█	█	█	█	█	█	█	█	█	█	█	█
128919	█	JUN2018	URTICARIA	* AMOXICILLIN	█	█	█	█	9	F	█
█	█	█	█	█	█	█	█	█	█	█	█

Serious Cases in Patients under 18 ...continued

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128197	█	APR2018	DRUG FEVER PANCYTOPENIA HEPATIC ENZYMES INCREASED DIARRHOEA	* PIPERACILLIN/TAZOBACTAM SODIUM CHLORIDE CALCIUM CARBONATE CARNITINE ALLOPURINOL	█	█	█	█	4	F	█
█	█	█									
█	█	█									
128028	█	APR2018	ANAPHYLACTIC REACTION	* CEPHAZOLIN PARACETAMOL CHLORHEXIDINE DEXAMETHASONE PROPOFOL	█	█	█	█	6	F	█
█	█	█									
128583	█	MAY2018	FLUSHING URTICARIA OEDEMA PERIORBITAL	* CEPHAZOLIN * KETAMINE FENTANYL ATROPINE ONDANSETRON HYDROCHLORIDE	█	█	█	█	13	M	█
█	█	█									
128767	█	MAY2018	ANAPHYLAXIS	* CEPHAZOLIN FENTANYL PROPOFOL ATRACURIUM SALBUTAMOL	█	█	█	█	11	M	█
█	█	█									

Serious Cases in Patients under 18 ...continued

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128922	[REDACTED]	JUN2018	ANAPHYLACTIC REACTION	* CEPHAZOLIN MIDAZOLAM FENTANYL PROPOFOL LIGNOCAINE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	9	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
128917	[REDACTED]	JUN2018	ERYTHEMA MULTIFORME MYOCARDITIS SHOCK CIRCULATORY FEVER ARTHRALGIA	* MINOCYCLINE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	14	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
128151	[REDACTED]	APR2018	ANAPHYLACTIC REACTION	* COTRIMOXAZOLE FLUTICASONE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	10	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Serious Cases in Patients under 18 ...continued

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
127972	[REDACTED]	APR2018	BRONCHOSPASM ANAPHYLACTIC REACTION	* PEGASPARGASE DEXAMETHASONE ONDANSETRON HYDROCHLORIDE SULFAMETHOXAZOLE/TRIMETHOPRIM OMEPRAZOLE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	8	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
128073	[REDACTED]	APR2018	C-REACTIVE PROTEIN POSITIVE INFLAMMATION FEELING UNWELL NEOPLASM NOS FEVER	* ADALIMUMAB * METHOTREXATE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	12	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Table 7: Serious cases reporting serious AEFI terms with vaccines in children Under 18 years

REPORT	ORIGIN	DATE	Severe	REACTIONS	VACCINE	AGE	SEX	OUTCOME
128057	[REDACTED]	APR2018	[REDACTED]	RASH ECZEMA STRIDOR	* DTaP-Hexa * PNEUMOCOCCAL VACC - 10 PARACETAMOL	5m	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
128535	[REDACTED]	MAY2018	[REDACTED]	SALIVA INCREASED CHOKING HYPOTONIA PALLOR APNOEA	* ROTA VIRUS VACCINE * DTaP-Hexa * PNEUMOCOCCAL VACC - 10	1m	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
129087	[REDACTED]	JUN2018	[REDACTED]	FEVER TWITCHING PALPITATION MOBILITY DECREASED PAIN	* HAEMOPHILUS B (HIBERIX) PNEUMOCOCCAL VACC - 10	15m	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Serious AEFI Terms

System Organ Class	AEFI
Alimentary	PAROTID ENLARGEMENT
	PAROTITIS
Application Site	ISR ABCESS
	ISR INFLAMMATION (SEVERE)
	ISR ABSCESS STERILE
Endocrine/Metabolic	LARYNGOTRACHEAL OEDEMA
	LARYNX OEDEMA
	ORCHITIS
Haematological	THROMBOCYTOPENIA
Musculoskeletal	ARTHRALGIA
	ARTHRITIS
	ARTHROPATHY
	ARTHROSIS
	OSTEOMYELITIS
Nervous System	CONVULSIONS
	CONVULSIONS GRAND MAL
	ENCEPHALITIS
	ENCEPHALOMYELITIS
	ENCEPHALOPATHY
	FEVER CONVULSIONS
	GUILLAIN-BARRE SYNDROME
	HYPOTONIC-HYPORESPONSIVE EPISODE (HHE)
	MENINGITIS
	MENINGITIS ASEPTIC
	MENINGOENCEPHALITIS
	NEURITIS
	NEURITIS CRANIAL
	NEURITIS MOTOR
	NEURITIS SENSORY
	OEDEMA CEREBRAL
	PETIT MAL CONVULSION
POLIOMYELITIS	

Serious AEFI Terms

System Organ Class	AEFI
Others	ALLERGIC REACTION
	ANAPHYLACTIC REACTION
	ANAPHYLACTIC SHOCK
	ANAPHYLACTOID REACTION
	ANAPHYLAXIS
	CRYING ABNORMAL
	DEATH
	FACE OEDEMA
	FEVER ≥ 40
	LYMPHADENOPATHY
	OEDEMA
	OEDEMA GENERALISED
	TONGUE OEDEMA
Resistance Mechanism Disorders	SEPSIS
	SEPTICAEMIA
	VACCINE FAILURE
Respiratory	APNOEA
	BRONCHOSPASM
	DYSPNOEA
	OEDEMA PULMONARY
Skin and Appendages	ABSCESS
	ACUTE GEN. ECZEMATOUS PUSTULOSIS
	ANGIOEDEMA
	ANGIOEUROTIC OEDEMA
	BULLOUS ERUPTION
	ECZEMA
	EPIDERMAL NECROLYSIS
	ERYTHEMA MULTIFORME
	PRURITUS
	STEVENS JOHNSON SYNDROME
	TOXIC EPIDERMAL NECROLYSIS
	URTICARIA

Table 8: Serious non-fatal cases causally associated with critical terms in patients over 80 years

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128048	[REDACTED]	APR2018	HEPATIC CIRRHOSIS	* ARTHREM CILAZAPRIL METOPROLOL ALLOPURINOL THYROXINE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	81	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
128881	[REDACTED]	JUN2018	DRUG INTERACTION DYSPNOEA INR INCREASED CONJUNCTIVAL HAEMORRHAGE	* WARFARIN * COTRIMOXAZOLE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	96	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
127968	[REDACTED]	APR2018	CEREBRAL INFARCTION MEDICINE INEFFECTIVE	* DABIGATRAN	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	87	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Serious Cases in Patients over 80 ...continued

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128495	[REDACTED]	MAY2018	GUILLAIN-BARRE SYNDROME	* INFLUENZA - QUADRIVALENT	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	82	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
128951	[REDACTED]	JUN2018	CONFUSION CONVULSIONS	* INFLUENZA - QUADRIVALENT METOPROLOL DABIGATRAN PARACETAMOL	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	85	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Table 9: Causal and Serious Cases in 18 to 80 age group

92 cases have been assessed Causal and Serious
108 suspect medicines involved

Table 9.1: ATC classification Overview

	ATC High Level Group	No. of Medicines	Percentage
A	Alimentary	3	2.8
B	Blood and Blood forming organs	11	10.2
C	Cardiovascular	3	2.8
D	Dermatological	2	1.8
G	Genito Urinary System and Sex Hormones	10	9.3
H	Systemic Hormones (excl Sex Hormones)	1	0.9
J	Anti-infectives	30	27.8
L	Antineoplastics and Immunomodulating Agents	7	6.5
M	Musculoskeletal	11	10.2
N	Nervous System	23	21.3
P	Antiparasitic Products, Insecticides and Repellents	0	
R	Respiratory System	2	1.8
S	Sensory Organs	0	
V	Miscellaneous	5	4.6
	<u>Total Suspect Medicines</u>	108	100.0

Table 9.2: ATC Detailed listing of Medicines

	ATC Group	Number	Total
A	Alimentary		3
A04A	Ondansetron hydrochloride	1	
A06A	Metamucil	1	
A10B	Metformin	1	
B	Blood and Blood forming organs		11
B01A	Dabigatran	4	
	Warfarin	1	
B02A	Tranexamic Acid	1	
B03A	Iron Carboxymaltose	4	
B03X	Erythropoietin	1	
C	Cardiovascular		3
C09A	Enalapril	1	
	Quinapril	1	
C10A	Simvastatin	1	
D	Dermatological		2
D08A	Chlorhexidine	2	0
G	Genito Urinary System and Sex Hormones		10
G02A	Carboprost	1	
	Dinoprostone	5	
G03A	Depo-Provera	1	
	Levien ED	1	
	Mirena	1	
G03H	Ginet 84	1	
H	Systemic Hormones (excl Sex Hormones)		1
H02A	Prednisone	1	
J	Anti-infectives		30
J01C	Amoxicillin	2	
	Amoxicillin/Clavulanic Acid	6	
	Flucloxacillin	4	
	Piperacillin/Tazobactam	1	
J01D	Ceftriaxone	1	
	Cefuroxime	2	
	Cephazolin	7	
	Meropenem	1	
J01E	Cotrimoxazole	1	
J01F	Erythromycin	1	
J01X	Ornidazole	1	
J07A	ADT (Adult/Double) Vaccine	1	
J07B	Influenza Quadrivalent	1	
	Varicella Vaccine - Shingles	1	

L	Antineoplastics and Immunomodulating Agents		7
L01B	Methotrexate	1	
L01X	Ibrutinib	1	
	Pembrolizumab	2	
L04A	Adalimumab	1	
	Leflunomide	2	
M	Musculoskeletal		11
M01A	Diclofenac	1	
	Ibuprofen	3	
	Parecoxib	1	
M03A	Rocuronium	3	
	Suxamethonium chloride	2	
M04A	Probenecid	1	
N	Nervous System		23
N01A	Remifentanil	1	
N01B	Lignocaine	1	
	Lignocaine w/Adrenaline	1	
N02A	Codeine	1	
	Methadone	1	
	Tramadol	1	
N05A	Clozapine	1	
	Quetiapine	1	
N05B	Buspirone Hydrochloride	1	
N06A	Citalopram	1	
	Nortriptyline	1	
	Paroxetine	1	
	Sertraline	1	
	Venlafaxine	8	
N06D	Memantine	1	
N07X	Dimethyl Fumarate	1	
P	Antiparasitic Products, Insecticides & Repellents		0
R	Respiratory		2
R03A	Salbutamol	1	
	Umeclidinium+Vilanterol	1	
S	Sensory Organs		0
V	Miscellaneous		5
V03A	Alcohol (Ethyl)	1	
V04C	Patent Blue V	2	
V08A	Iohexol	2	
	Total Medicines		108

TABLE 9.3: Causal and Serious Cases in 18 to 80 age group

Note: 108 suspect medicines (indicated by an asterisk) have been involved on 92 cases. Each case appears in the ATC group of the suspect medicine which is highlighted. Cases with multiple suspects appear multiple times and can be in more than one ATC group

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
ATC = Alimentary											
128875	██████	JUN2018	ANAPHYLAXIS	* ONDANSETRON HYDROCHLORIDE	█		████	████	52	F	████████████████
129040	██████	JUN2018	OESOPHAGEAL OBSTRUCTION PRODUCT PROBLEM	* METAMUCIL	█	█	████	████	48	F	████████████████
128880	██████	JUN2018	ACIDOSIS LACTIC ANURIA BRADYCARDIA HYPOTENSION	* METFORMIN	█	█		████	70	M	████████████
ATC = Blood and Blood forming organs											
127955	██████	APR2018	GI HAEMORRHAGE	* DABIGATRAN * NSAID UNCLASSIFIED FRUSEMIDE AMIODARONE SPIRONOLACTONE	█	████	████	████	63	M	████████████████
127967	██████	APR2018	TRANSIENT ISCHAEMIC ATTACK MEDICINE INEFFECTIVE	* DABIGATRAN	█	████	████	████	75	M	████████████████
128349	██████	MAY2018	THROMBOSIS CEREBELLAR ARTERIAL PRODUCT STORAGE ERROR MEDICINE INEFFECTIVE	* DABIGATRAN	█	████	████	████	54	M	████████████
128609	████	MAY2018	HAEMOPTYSIS EMBOLISM PULMONARY DRUG LEVEL DECREASED	* DABIGATRAN LACTULOSE MORPHINE SULPHATE OMEPRAZOLE IBUPROFEN	█	████	████	████	44	M	████████████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128794	█	JUN2018	INR INCREASED DRUG INTERACTION	* WARFARIN CLINICIANs LIVER PROTECT PLUS	█	█ █	█	█	46	F	█
127966	█	APR2018	ANAPHYLACTIC SHOCK	* SUXAMETHONIUM CHLORIDE * TRANEXAMIC ACID * CARBOPROST OXYTOCIN PROPOFOL	█	█	█	█	29	F	█
127937	█	APR2018	INFLUENZA-LIKE SYMPTOMS HYPERAESTHESIA MUSCLE WEAKNESS DYSPNOEA PERIPHERAL COLDNESS	* IRON CARBOXYMALTOSE	█		█	█	33	F	█
127938	█	APR2018	HYPOPHOSPHATAEMIA	* IRON CARBOXYMALTOSE PANCREATIN MULTIVITAMINS	█	█	█	█	62	M	█
127939	█	APR2018	HYPOPHOSPHATAEMIA	* IRON CARBOXYMALTOSE	█	█ █	█	█	44	F	█
128898	█	JUN2018	LIPS SWELLING NON-SPECIFIC DYSPNOEA URTICARIA ANAPHYLAXIS	* IRON CARBOXYMALTOSE	█	█ █	█	█	33	F	█
128117	█	APR2018	APLASIA, PURE RED CELL	* ERYTHROPOIETIN SIMVASTATIN ALLOPURINOL DOXAZOSIN ZOPICLONE	█	█	█	█	75	M	█
ATC = Cardiovascular											
128227	█	APR2018	ANGIOEDEMA	* ENALAPRIL ROSUVASTATIN OMEPRAZOLE	█	█	█	█	67	M	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128228	█	APR2018	ANGIOEDEMA THROAT TIGHTNESS	* QUINAPRIL ATORVASTATIN	█	█	█	█	76	F	█
128435	█	MAY2018	HEPATOCELLULAR DAMAGE BILIRUBINAEMIA C-REACTIVE PROTEIN POSITIVE FEVER ARTHRALGIA	* SIMVASTATIN	█	█	█	█	75	M	█
ATC = Dermatological											
128225	█	APR2018	URTICARIA ANGIOEDEMA HYPOTENSION	* LIGNOCAINE CENTRUM LORATADINE * CHLORHEXIDINE	█		█	█	61	F	█
128582	█	MAY2018	ANAPHYLACTIC REACTION	* SUXAMETHONIUM CHLORIDE * CEPHAZOLIN * CHLORHEXIDINE FENTANYL PROPOFOL	█		█	█	23	F	█
ATC = Genito Urinary System and Sex Hormones											
127966	█	APR2018	ANAPHYLACTIC SHOCK	* SUXAMETHONIUM CHLORIDE * TRANEXAMIC ACID * CARBOPROST OXYTOCIN PROPOFOL	█	█	█	█	29	F	█
128968	█	JUN2018	ABRUPTIO PLACENTAE	* DINOPROSTONE	█	█	█	█	29	F	█
128969	█	JUN2018	FOETAL DISTRESS	* DINOPROSTONE	█	█	█	█	31	F	█
128971	█	JUN2018	FOETAL DISTRESS	* DINOPROSTONE	█	█	█	█	30	F	█
128972	█	JUN2018	FOETAL DISTRESS FOETAL BRADYCARDIA	* DINOPROSTONE	█	█	█	█	22	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
129002	█	JUN2018	UTERINE HYPERTONUS FOETAL DISTRESS	* DINOPROSTONE	█	█ █	█	█	38	F	█
129041	█	JUN2018	ANAPHYLAXIS RIGORS TACHYCARDIA HYPOTENSION SWELLING LOCALISED	* DEPO-PROVERA MEDROXYPROGESTERONE SALBUTAMOL VALACICLOVIR	█	█ █	█	█	26	F	█
128070	█	APR2018	EMBOLISM PULMONARY BRAND SWITCH	* LEVLEN ED	█	█ █	█	█	30	F	█
128244	█	APR2018	VAGINAL HAEMORRHAGE	* MIRENA	█		█	█	46	F	█
128843	█	JUN2018	EMBOLISM PULMONARY	* GINET 84	█	█ █	█	█	18	F	█
ATC = Systemic Hormones (excluding Sex Hormones)											
128840	█	JUN2018	INFECTION BACTERIAL MENINGITIS SEPTIC ARTHRITIS ABSCESS CNS	* LEFLUNOMIDE * PREDNISONE ETORICOXIB GABAPENTIN PARACETAMOL	█	█ █	█	█	57	F	█
ATC = Anti-infectives											
128766	█	MAY2018	ANAPHYLAXIS	* AMOXICILLIN PARACETAMOL ASCORBIC ACID	█	█ █	█	█	38	M	█
128959	█	JUN2018	ERYTHEMA MULTIFORME	* AMOXICILLIN	█	█ █	█	█	50	F	█
128196	█	APR2018	ERYTHRODERMA RENAL IMPAIRMENT CONJUNCTIVITIS DEHYDRATION HYPOPHOSPHATAEMIA	* AMOXICILLIN/CLAVULANIC ACID LOSARTAN DORZOLAMIDE/TIMOLOL LATANOPROST WARFARIN	█	█ █	█	█	58	M	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128750	██████	MAY2018	ANAPHYLAXIS	* AMOXICILLIN/CLAVULANIC ACID	█	██████	██████	██████	55	M	████████████████████
128764	██████	MAY2018	ANAPHYLAXIS FLUSHING TONGUE SWELLING NON-SPECIFIC LIPS SWELLING NON-SPECIFIC PRURITUS	* AMOXICILLIN/CLAVULANIC ACID	█	██████	██████	██████	72	F	████████████████████
129025	██████	JUN2018	THROAT TIGHTNESS URTICARIA SKIN TEST POSITIVE HOARSENESS NASAL CONGESTION	* AMOXICILLIN/CLAVULANIC ACID * FLUCLOXACILLIN * IBUPROFEN	█		██████	██████	56	F	████████████████████
129104	██████	JUN2018	URTICARIA ANAPHYLACTIC REACTION	* AMOXICILLIN/CLAVULANIC ACID	█	██████	██████	██████	40	F	████████████████████
128289	██████	MAY2018	UNCONSCIOUSNESS RASH PRURITIC	* IBUPROFEN * ADT (ADULT/DOUBLE) VACCINE * AMOXICILLIN/CLAVULANIC ACID * PARACETAMOL	█	██████	██████	██████	55	M	████████████████████
127941	██████	APR2018	HEPATIC ENZYMES INCREASED BILIRUBINAEMIA	* FLUCLOXACILLIN	█	█ █	██████	██████	37	M	████████████████████
128383	██████	MAY2018	SKIN TEST POSITIVE URTICARIA ANGIOEDEMA	* FLUCLOXACILLIN	█	█ █	██████	██████	27	F	████████████████████
128812	██████	JUN2018	ANAPHYLAXIS	* FLUCLOXACILLIN * BUDESONIDE/EFORMOTEROL * OMEPRAZOLE * CHOLECALCIFEROL * IBUPROFEN	█	██████	██████	██████	62	M	████████████████████
128904	██████	JUN2018	ANAPHYLAXIS ANGIOEDEMA HYPOXIA	* FLUCLOXACILLIN * ACE INHIBITOR (NOS)	█				56	M	████████████████████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128064	██████	APR2018	NEUTROPENIA RASH MACULO-PAPULAR	* PIPERACILLIN/TAZOBACTAM	█	█ █	████	████	49	F	████████████████
128879	██████	JUN2018	DRESS SYNDROME	* CEFTRIAXONE CIPROFLOXACIN SPIRONOLACTONE WARFARIN	█	█ █	████	████	39	M	██████████
128027	██████	APR2018	DERMATITIS LICHENOID EOSINOPHILIA HEPATIC FUNCTION ABNORMAL	* CEFUROXIME	█		████	████	62	M	████████████████
128905	██████	JUN2018	ANAPHYLAXIS SKIN TEST POSITIVE	* CEFUROXIME FENTANYL MORPHINE SULPHATE PROPOFOL ATRACURIUM	█		████	████	66	F	████████████████
128017	██████	APR2018	ANAPHYLAXIS SKIN TEST POSITIVE	* CEPHAZOLIN DEXAMETHASONE METRONIDAZOLE OXYTOCIN PROPOFOL	█	█ █	████	████	21	F	████████████████
128159	██████	APR2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* CEPHAZOLIN PROPOFOL MIDAZOLAM BUPIVACAINE LIGNOCAINE	█	█ █	████	████	42	M	████████████████
128529	██████	MAY2018	ANAPHYLAXIS SKIN TEST POSITIVE	* CEPHAZOLIN BUPIVACAINE MORPHINE SULPHATE FENTANYL PROPOFOL	█		████	████	46	M	████████████████
128582	██████	MAY2018	ANAPHYLACTIC REACTION	* SUXAMETHONIUM CHLORIDE * CEPHAZOLIN * CHLORHEXIDINE FENTANYL PROPOFOL	█		████	████	23	F	████████████████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128706	██████	MAY2018	ANAPHYLAXIS SKIN TEST POSITIVE	* CEPHAZOLIN PROPOFOL MIDAZOLAM FENTANYL ROCURONIUM	█	█ █	█	█	36	F	████████████████████
128975	██████	JUN2018	ANAPHYLAXIS	* CEPHAZOLIN MIDAZOLAM LIGNOCAINE IODINE EXTERNAL ROPIVACAINE	█	█	█	█	57	M	████████████████████
129026	██████	JUN2018	HYPOTENSION ERYTHEMA TONGUE OEDEMA SKIN TEST NEGATIVE	* CEPHAZOLIN FENTANYL PROPOFOL ROCURONIUM KETAMINE	█		█	█	60	M	████████████████████
128920	██████	JUN2018	NEUTROPENIA TASTE PERVERSION EAR ACHE GAMMA-GT INCREASED ALKALINE PHOSPHATASE SERUM INCR	* MEROPENEM PARACETAMOL	█	█ █	█	█	29	F	████████████████████
128695	██████	MAY2018	STEVENS JOHNSON SYNDROME	* COTRIMOXAZOLE	█	█ █	█	█	69	F	████████████████████
128445	██████	MAY2018	DRUG INTERACTION CONSCIOUSNESS DECREASED CYANOSIS	I PAROXETINE I QUETIAPINE I ERYTHROMYCIN I METHADONE I ZOPICLONE	█	█	█	█	28	F	████████████████████
129122	██████	JUN2018	DRUG - ALCOHOL INTERACTION UNCONSCIOUSNESS MYOCLONIC JERKS APNOEA FLUSHING	* ORNIDAZOLE * ALCOHOL (ETHYL) CHLORPROMAZINE METHAMPHETAMINE	█	█ █ █	█	█	21	F	████████████████████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128289	██████	MAY2018	UNCONSCIOUSNESS RASH PRURITIC	* IBUPROFEN * ADT (ADULT/DOUBLE) VACCINE * AMOXICILLIN/CLAVULANIC ACID PARACETAMOL	█	█	█	█	55	M	██████
128698	█	MAY2018	ARM PAIN HEAVINESS IN LIMBS INJECTION SITE PAIN MOVEMENTS REDUCED NEUROPATHY PERIPHERAL	* INFLUENZA - QUADRIVALENT CITALOPRAM HYDROXOCOBALAMIN CETIRIZINE IBUPROFEN	█	█	█	█	66	F	██████
128467	█	MAY2018	ATAXIA FACIAL PALSY	* VARICELLA VACCINE - SHINGLES	█	█	█	█	72	F	██████
ATC = Antineoplastics and Immunomodulating Agents											
128769	██████	MAY2018	STEVENS JOHNSON SYNDROME DRUG LEVEL INCREASED PANCYTOPENIA SEPTICAEMIA MEDICATION ERROR	* METHOTREXATE	█	█	█	█	30	F	██████
129008	██████	JUN2018	PHOTOPHOBIA JOINT EFFUSION HEADACHE PROGRESSION OF DISEASE	* IBRUTINIB	█	█	█	█	59	F	██████
127949	██████	APR2018	COLITIS ULCERATIVE	* PEMBROLIZUMAB	█		█	█	50	M	██████
128023	██████	APR2018	INFECTION VIRAL HYPOTENSION POSTURAL NAUSEA	* PEMBROLIZUMAB	█		█	█	69	F	██████
124567	██████	MAY2018	FEVER INFECTION CYST NOS	* ADALIMUMAB	█	█	█	█	42	M	██████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128094	██████	APR2018	PANCREATITIS	* LEFLUNOMIDE DAIVOBET 50/500 CITALOPRAM	█	█	█	█	41	M	██████
128840	██████	JUN2018	INFECTION BACTERIAL MENINGITIS SEPTIC ARTHRITIS ABSCESS CNS	* LEFLUNOMIDE * PREDNISONE ETORICOXIB GABAPENTIN PARACETAMOL	█	█	█	█	57	F	██████
ATC = Musculoskeletal											
127970	██████	APR2018	NEPHRITIS INTERSTITIAL	* DICLOFENAC CODEINE NORTRIPTYLINE MONTELUKAST SODIUM AZATHIOPRINE	█	█	█	█	18	F	██████
128500	██████	MAY2018	ANGIOEDEMA URTICARIA	* IBUPROFEN ALCOHOL (ETHYL)	█		█	█	47	F	██████████████
129025	██████	JUN2018	THROAT TIGHTNESS URTICARIA SKIN TEST POSITIVE HOARSENESS NASAL CONGESTION	* AMOXICILLIN/CLAVULANIC ACID FLUCLOXACILLIN * IBUPROFEN	█		█	█	56	F	██████████████
128289	██████	MAY2018	UNCONSCIOUSNESS RASH PRURITIC	* IBUPROFEN * ADT (ADULT/DOUBLE) VACCINE * AMOXICILLIN/CLAVULANIC ACID PARACETAMOL	█	█	█	█	55	M	██████
128055	██████	APR2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* PARECOXIB ATRACURIUM MORPHINE SULPHATE CEFUROXIME METRONIDAZOLE	█		█	█	46	M	██████████████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
127919	█	APR2018	ANAPHYLAXIS SKIN TEST POSITIVE	* ROCURONIUM PROPOFOL MIDAZOLAM	█		█	█	28	F	█
127920	█	APR2018	SKIN TEST POSITIVE ANAPHYLACTIC SHOCK	* ROCURONIUM PROPOFOL MIDAZOLAM FENTANYL FLUTICASONE+VILANTEROL	█		█	█	77	M	█
128956	█	JUN2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* ROCURONIUM	█		█	█	61	F	█
127966	█	APR2018	ANAPHYLACTIC SHOCK	* SUXAMETHONIUM CHLORIDE * TRANEXAMIC ACID * CARBOPROST OXYTOCIN PROPOFOL	█	█	█	█	29	F	█
128582	█	MAY2018	ANAPHYLACTIC REACTION	* SUXAMETHONIUM CHLORIDE * CEPHAZOLIN * CHLORHEXIDINE FENTANYL PROPOFOL	█		█	█	23	F	█
128976	█	JUN2018	ANAPHYLAXIS	* PROBENECID	█		█	█	42	M	█
ATC = Nervous System											
128903	█	JUN2018	ANAPHYLAXIS SKIN TEST POSITIVE	* REMIFENTANIL	█		█	█	48	F	█
128225	█	APR2018	URTICARIA ANGIOEDEMA HYPOTENSION	* LIGNOCAINE CENTRUM LORATADINE * CHLORHEXIDINE	█		█	█	61	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
129039	█	JUN2018	CONSCIOUSNESS DECREASED BRADYCARDIA HYPOTENSION	* LIGNOCAINE w/ADRENALINE	█		█	█	36	F	█
128596	█	MAY2018	INTENTIONAL OVERDOSE MYOCLONUS PRURITUS URINARY RETENTION FLUSHING	* CODEINE * SERTRALINE * BUSPIRONE HYDROCHLORIDE * NORTRIPTYLINE PANTOPRAZOLE	█	█	█	█	29	F	█
128445	█	MAY2018	DRUG INTERACTION CONSCIOUSNESS DECREASED CYANOSIS	I PAROXETINE I QUETIAPINE I ERYTHROMYCIN I METHADONE ZOPICLONE	█	█	█	█	28	F	█
129062	█	JUN2018	CONVULSIONS	* TRAMADOL AMOXICILLIN/CLAVULANIC ACID METRONIDAZOLE LEVETIRACETAM THYROXINE	█	█	█	█	31	F	█
128328	█	MAY2018	SEPSIS NEUTROPENIA LEUCOPENIA	* CLOZAPINE	█		█	█	52	F	█
128445	█	MAY2018	DRUG INTERACTION CONSCIOUSNESS DECREASED CYANOSIS	I PAROXETINE I QUETIAPINE I ERYTHROMYCIN I METHADONE ZOPICLONE	█	█	█	█	28	F	█
128596	█	MAY2018	INTENTIONAL OVERDOSE MYOCLONUS PRURITUS URINARY RETENTION FLUSHING	* CODEINE * SERTRALINE * BUSPIRONE HYDROCHLORIDE * NORTRIPTYLINE PANTOPRAZOLE	█	█	█	█	29	F	█
128436	█	MAY2018	TREMOR	* CITALOPRAM MELATONIN	█	█	█	█	23	F	█

128596	██████	MAY2018	INTENTIONAL OVERDOSE MYOCLONUS PRURITUS URINARY RETENTION FLUSHING	* CODEINE * SERTRALINE * BUSPIRONE HYDROCHLORIDE * NORTRIPTYLINE PANTOPRAZOLE	██████	██████	██████	██████	29	F	██████
128445	██████	MAY2018	DRUG INTERACTION CONSCIOUSNESS DECREASED CYANOSIS	PAROXETINE QUETIAPINE ERYTHROMYCIN METHADONE ZOPICLONE	██████	██████	██████	██████	28	F	██████████████
128596	██████	MAY2018	INTENTIONAL OVERDOSE MYOCLONUS PRURITUS URINARY RETENTION FLUSHING	* CODEINE * SERTRALINE * BUSPIRONE HYDROCHLORIDE * NORTRIPTYLINE PANTOPRAZOLE	██████	██████	██████	██████	29	F	██████
128350	██████	MAY2018	DRUG WITHDRAWAL SYNDROME BRAND SWITCH	* VENLAFAXINE	██████	██████	██████	██████	42	M	██████
128351	██████	MAY2018	SUICIDE ATTEMPT DEPRESSION BRAIN ZAP PARONIRIA BRAND SWITCH	* VENLAFAXINE TOPIRAMATE ATORVASTATIN CHOLECALCIFEROL ALLOPURINOL	██████	██████	██████	██████	49	M	██████
128441	██████	MAY2018	BRAND SWITCH THERAPEUTIC RESPONSE DECREASED NAUSEA SUICIDAL TENDENCY DIZZINESS	* VENLAFAXINE	██████	██████	██████	██████	64	F	██████
128552	██████	MAY2018	BRAND SWITCH SUICIDAL IDEATION THERAPEUTIC RESPONSE DECREASED THOUGHTS OF SELF HARM PAIN	* VENLAFAXINE	██████	██████	██████	██████	48	F	██████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128694	█	MAY2018	THERAPEUTIC RESPONSE DECREASED BRAND SWITCH TWITCHING TREMOR SUICIDAL IDEATION	* VENLAFAXINE BUPROPION HYDROCHLORIDE QUETIAPINE BENDROFLUAZIDE CANDESARTAN	█	█	█	█	50	F	█
128739	█	MAY2018	THERAPEUTIC RESPONSE DECREASED BRAND SWITCH HEADACHE SUICIDAL IDEATION MYALGIA	* VENLAFAXINE	█	█	█	█	36	F	█
128740	█	MAY2018	ANXIETY BRAIN ZAP THERAPEUTIC RESPONSE DECREASED FLUSHING BRAND SWITCH	* VENLAFAXINE	█	█	█	█	48	F	█
128955	█	JUN2018	THERAPEUTIC RESPONSE DECREASED BRAND SWITCH SUICIDAL IDEATION ANXIETY	* VENLAFAXINE MIRTAZAPINE	█	█	█	█	58	F	█
127942	█	APR2018	CONVULSIONS	* MEMANTINE	█	█	█	█	53	M	█
128020	█	APR2018	PRURITUS NAUSEA VOMITING HEADACHE FATIGUE	* DIMETHYL FUMARATE	█	█	█	█	50	F	█
ATC = Respiratory											
128229	█	APR2018	RASH DYSпноEA HOARSENESS DYSPHAGIA MEDICATION ERROR	* SALBUTAMOL FLUTICASONE DIHYDROCODEINE PANTOPRAZOLE PARACETAMOL/CODEINE	█	█	█	█	69	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	OUTCOME
128928	██████	JUN2018	DIZZINESS HEADACHE MALAISE CHEST DISCOMFORT	* UMECLIDINIUM+VILANTEROL SALBUTAMOL LOSARTAN TIOTROPIUM BROMIDE	█	█ █	█	█	75	F	██████████
ATC = Miscellaneous											
129122	██████	JUN2018	DRUG - ALCOHOL INTERACTION UNCONSCIOUSNESS MYOCLONIC JERKS APNOEA FLUSHING	* ORNIDAZOLE * ALCOHOL (ETHYL) CHLORPROMAZINE METHAMPHETAMINE	█	█ █	█ █	█ █	21	F	██████████
128182	██████	APR2018	ANAPHYLAXIS SKIN TEST POSITIVE	* PATENT BLUE V FENTANYL KETAMINE PARECOXIB CEPHAZOLIN	█	█ █	█ █	█ █	58	F	██████████
129048	██████	JUN2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* PATENT BLUE V LIGNOCAINE FENTANYL CEPHAZOLIN ROPIVACAINE	█	█ █	█ █	█ █	47	F	██████████
128255	██████	APR2018	DYSPNOEA THROAT TIGHTNESS PARAESTHESIA	* IOHEXOL METFORMIN PREDNISONE CANDESARTAN ACETYLSALICYLIC ACID	█	█ █	█ █	█ █	57	M	██████████
128836	██████	JUN2018	DYSPNOEA THROAT SWELLING NON-SPECIFIC TONGUE SWELLING NON-SPECIFIC ANAPHYLAXIS	* IOHEXOL	█	█ █	█ █	█ █	46	F	██████████